KELLY TRAN: Open Payments
NPI 1851773188 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 44 payments from 12 companies in 2025. Trend: 2023 $931 · 2024 $1,048 · 2025 $989
Food & beverage: $965Consulting: $24
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $232 |
| GlaxoSmithKline, LLC. | 13 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $159 |
| Regeneron Healthcare Solutions, Inc. | 4 | $113 |
| Novartis Pharmaceuticals Corporation | 4 | $96 |
| Cycle Pharmaceuticals Inc | 2 | $48 |
| GENZYME CORPORATION | 2 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $26 |
| ADMA BioManufacturing LLC | 1 | $24 |
Products named: DUPIXENT, AIRSUPRA, TRELEGY ELLIPTA, NUCALA, CUVITRU, Rhapsido, TAKHZYRO, Sajazir.
Industry payments across NV — which companies pay providers there.
